Developing breakthrough AXL therapeutics to improve patients' lives

Developing breakthrough AXL therapeutics to improve patients' lives
Background
DecorationDecoration

Learn About Us

Read more

Latest news

Read more
Old woman

BerGenBio is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases including cancer and severe respiratory infections

Recent News

BerGenBio announces Nature Communications Publication of BGBC003 Ph2 data in relapsed/refractory Acute Myeloid Leukemia patients

Read more

BerGenBio announces advancement of its strategic review

Read more

BerGenBio Fourth Quarter Results 2024

Read more

BerGenBio announces discontinuation of 1L STK11M NSCLC study and exploration of strategic alternatives

Read more

BerGenBio ASA: Invitation to fourth quarter 2024 results webcast

Read more

BerGenBio Announces First Patient Entered Into Advanced Adenocarcinoma Lung Cancer Trial

Read more

BerGenBio to Present Company Update at DNB Nordic Healthcare Conference

Read more

BerGenBio Appoints Olav Hellebø as CEO

Read more

BerGenBio Third Quarter Results 2024

Read more
All news